Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma

NCT02298348 is registered in ClinicalTrials.gov with New Approaches to Neuroblastoma Therapy Consortium as lead sponsor.

NCT NCT02298348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02298348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 8, 2015
Completion date
December 31, 2026
Enrollment
18 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma